TG Therapeutics, Inc.
TG Therapeutics, Inc. (0VGI.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for TG Therapeutics, Inc. (0VGI.L), featuring income statements, balance sheets, and cash flow data.
TG Therapeutics, Inc. (0VGI.L) Income Statement & Financial Overview
Explore comprehensive income reports for TG Therapeutics, Inc. 0VGI.L, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $141.15M | $120.86M | $108.19M | $83.88M |
| Cost of Revenue | $18.94M | $15.54M | $15.40M | $9.34M |
| Gross Profit | $122.21M | $105.31M | $92.79M | $74.54M |
| Gross Profit Ratio | $0.87 | $0.87 | $0.86 | $0.89 |
| R&D Expenses | $31.78M | $46.36M | $23.87M | $20.14M |
| SG&A Expenses | $55.59M | $50.33M | $38.96M | $41.97M |
| Operating Expenses | $87.37M | $96.69M | $62.84M | $62.10M |
| Total Costs & Expenses | $106.31M | $112.23M | $78.24M | $71.44M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $6.72M | $6.76M | $7.06M | $10.83M |
| Depreciation & Amortization | $0.00 | $56000.00 | $62000.00 | $64000.00 |
| EBITDA | $37.64M | $12.28M | $32.07M | $15.10M |
| EBITDA Ratio | $0.27 | $0.10 | $0.30 | $0.18 |
| Operating Income | $34.84M | $8.62M | $29.95M | $12.43M |
| Operating Income Ratio | $0.25 | $0.07 | $0.28 | $0.15 |
| Other Income/Expenses (Net) | -$3.92M | -$3.15M | -$4.50M | -$8.17M |
| Income Before Tax | $30.92M | $5.47M | $25.45M | $4.27M |
| Income Before Tax Ratio | $0.22 | $0.05 | $0.24 | $0.05 |
| Income Tax Expense | $2.73M | $408000.00 | $2.12M | $388000.00 |
| Net Income | $28.19M | $5.06M | $23.33M | $3.88M |
| Net Income Ratio | $0.20 | $0.04 | $0.22 | $0.05 |
| EPS | $0.19 | $0.03 | $0.16 | $0.03 |
| Diluted EPS | $0.17 | $0.03 | $0.15 | $0.02 |
| Weighted Avg Shares Outstanding | $146.74M | $146.68M | $145.32M | $145.10M |
| Weighted Avg Shares Outstanding (Diluted) | $162.56M | $162.77M | $160.24M | $160.71M |
The company's financials show resilient growth, with revenue advancing from $83.88M in Q3 2024 to $141.15M in Q2 2025. Gross profit remained healthy with margins at 87% in Q2 2025 compared to 89% in Q3 2024. Operating income hit $34.84M last quarter, sustaining a consistent 25% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $37.64M. Net income rose to $28.19M, while earnings per share reached $0.19. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan